Malaysia
Search
Sign In
Change Password
Points
Sign Out
Infectious Diseases
Top Medical News
A large study conducted in Israel has suggested that the effectiveness of the BNT162b2 vaccine against COVID-19 decreases over time.
Long-term exposure to particulate matter ≤2.5 μm (PM2.5) results in increased admission to hospital for COVID-19, according to a recent study.
A recent Singapore meta-analysis of randomized controlled trials (RCT) has found no clear clinical benefit to using convalescent plasma (CP) for patients with the coronavirus disease 2019 (COVID-19), especially in those with severe disease.
A single injection of tocilizumab is enough to weaken systemic inflammation for up to 7 days in patients with the coronavirus disease 2019 (COVID-19), a recent study suggests.
Consumption of a specific probiotic has been linked to reductions in dengue symptoms, a new study reveals.
The coverage of influenza vaccination for Medicare beneficiaries remains poor, reports a study, noting missed opportunities despite availability of vaccines with no copayment. In addition, there are still disparities in vaccination uptake by race/ethnicity.
Adults newly diagnosed with COVID-19 in outpatient settings and enrolled in an automated remote monitoring service are less likely to succumb to the disease potentially due to more frequent telemedicine encounters and earlier presentation to the emergency department (ED), a study has shown.
Special Reports
That COVID-19 mostly spared children might be changing. The Delta variant has taken a severe, unthinkable toll on kids – at least in Arkansas, US, reports an expert at IDWeek 2021.
While rapid antigen test is less sensitive than conventional nucleic acid amplification test (NAAT) such as RT-PCR* in detecting SARS-CoV-2 virus, “a test does not have to be perfect to be clinically useful,” said Professor Angela Caliendo during a session in IDWeek 2021 — echoing the maxim that perfect should not be the enemy of good in the pandemic era.
A large retrospective study from the US, presented at IDWeek 2021, has shown that the Abbott ID NOW rapid molecular COVID-19 assay is highly sensitive and specific at detecting SARS-CoV-2 infection in a paediatric population.
Isavuconazole 100 mg hard cap and 200 mg infusion conc
Same-day pre-event screening for SARS-CoV-2 using antigen-detecting rapid diagnostic tests (Ag-RDT) may enable the resumption of large-scale indoor events which were halted or had their attendance capacity reduced during the COVID-19 pandemic, according to a study from Spain presented at ECCMID 2021.
A rapid and affordable test for diagnosing COVID-19 outside the walls of the healthcare units could improve case-finding, contact tracing, and infection control, says an expert during a pre-ECCMID 2021 session.
While RT-PCR is the current gold standard to confirm a SARS-CoV-2 infection, antigen rapid test (ART) for COVID-19 allows for quick detection of SARS-CoV-2 and thus fast triaging of infected patients requiring isolation at the population level, according to studies presented at ECCMID 2021.
Conference Reports
The oral selective JAK1/2 inhibitor baricitinib significantly reduces the risk of death in critically ill COVID-19 patients who are on invasive mechanical ventilation (IMV) or ECMO*, when used in combination with standard care, according to the addendum study of the COV-BARRIER trial presented at IDWeek 2021.
That COVID-19 mostly spared children might be changing. The Delta variant has taken a severe, unthinkable toll on kids – at least in Arkansas, US, reports an expert at IDWeek 2021.
While rapid antigen test is less sensitive than conventional nucleic acid amplification test (NAAT) such as RT-PCR* in detecting SARS-CoV-2 virus, “a test does not have to be perfect to be clinically useful,” said Professor Angela Caliendo during a session in IDWeek 2021 — echoing the maxim that perfect should not be the enemy of good in the pandemic era.
The monoclonal antibody (mAb) combination therapy comprising BRII-196 and BRII-198 significantly reduced the risk of hospitalization and death by more than three-quarters in non-hospitalized COVID-19 patients who were at high risk of worsening illness, according to an interim analysis of the ACTIV*-2 trial presented at IDWeek 2021.
A large retrospective study from the US, presented at IDWeek 2021, has shown that the Abbott ID NOW rapid molecular COVID-19 assay is highly sensitive and specific at detecting SARS-CoV-2 infection in a paediatric population.
Data presented at ID Week 2021 show that Clostridioides difficile (CDI), which is known to be hospital-associated, is highly prevalent even in nonhealthcare settings.
Intramuscular administration of single-dose AZD7442, a combination of two long-acting monoclonal antibodies (tixagevimab and cilgavimab), significantly reduced the risk of developing symptomatic COVID-19 in adults, according to the PROVENT* study presented at IDWeek 2021.
